The Epidemiology of Invasive Group A Streptococcal Infection and Potential Vaccine Implications: United States,
|
|
- Joan Oliver
- 6 years ago
- Views:
Transcription
1 MAJOR ARTICLE The Epidemiology of Invasive Group A Streptococcal Infection and Potential Vaccine Implications: United States, Rosalyn E. O Loughlin, 1,2 Angela Roberson, 1 Paul R. Cieslak, 5 Ruth Lynfield, 6 Ken Gershman, 7 Allen Craig, 8 Bernadette A. Albanese, 9 Monica M. Farley, 3,4 Nancy L. Barrett, 10 Nancy L. Spina, 11 Bernard Beall, 1 Lee H. Harrison, 12 Arthur Reingold, 13 and Chris Van Beneden, 1 for the Active Bacterial Core Surveillance Team 1 Respiratory Diseases Branch, National Center for Immunization and Respiratory Diseases, and 2 Epidemic Intelligence Service, Centers for Disease Control and Prevention, 3 Emory University School of Medicine, and 4 Atlanta Veterans Affairs Medical Center, Atlanta, Georgia; 5 Oregon Department of Human Services, Portland; 6 Minnesota Department of Health, Minneapolis; 7 Colorado Department Public Health and Environment, Denver; 8 Tennessee Department of Health, Nashville; 9 New Mexico Department of Health, Santa Fe; 10 Connecticut Department of Public Health, Hartford; 11 New York State Department of Health, Albany; 12 Johns Hopkins Bloomberg School of Public Health, Baltimore; and 13 University of California, Berkeley (See the editorial commentary by Cohen-Poradosu and Kasper on pages 863 5) Background. Invasive group A Streptococcus (GAS) infection causes significant morbidity and mortality in the United States. We report the current epidemiologic characteristics of invasive GAS infections and estimate the potential impact of a multivalent GAS vaccine. Methods. From January 2000 through December 2004, we collected data from Centers for Disease Control and Prevention s Active Bacterial Core surveillance (ABCs), a population-based system operating at 10 US sites (2004 population, 29.7 million). We defined a case of invasive GAS disease as isolation of GAS from a normally sterile site or from a wound specimen obtained from a patient with necrotizing fasciitis or streptococcal toxic shock syndrome in a surveillance area resident. All available isolates were emm typed. We used US census data to calculate rates and to make age- and race-adjusted national projections. Results. We identified 5400 cases of invasive GAS infection (3.5 cases per 100,000 persons), with 735 deaths (case-fatality rate, 13.7%). Case-fatality rates for streptococcal toxic shock syndrome and necrotizing fasciitis were 36% and 24%, respectively. Incidences were highest among elderly persons (9.4 cases per 100,000 persons), infants (5.3 cases per 100,000 persons), and black persons (4.7 cases per 100,000 persons) and were stable over time. We estimate that ,500 cases of invasive GAS infection occur in the United States annually, resulting in deaths. The emm types in a proposed 26-valent vaccine accounted for 79% of all cases and deaths. Independent factors associated with death include increasing age; having streptococcal toxic shock syndrome, meningitis, necrotizing fasciitis, pneumonia, or bacteremia; and having emm types 1, 3, or 12. Conclusions. GAS remains an important cause of severe disease in the United States. The introduction of a vaccine could significantly reduce morbidity and mortality due to these infections. Invasive infections caused by group A Streptococcus (GAS) or Streptococcus pyogenes include sepsis, bacteremic pneumonia, necrotizing fasciitis (NF), and streptococcal toxic shock syndrome (STSS). GAS also causes noninvasive disease, most commonly manifested as Received 9 February 2007; accepted 23 May 2007; electronically published 29 August Reprints or correspondence: Dr. Rosalyn O Loughlin, Centers for Disease Control and Prevention, 1600 Clifton Rd. NE, MS C-23, Atlanta, GA (bwf0@cdc.gov). Clinical Infectious Diseases 2007; 45: by the Infectious Diseases Society of America. All rights reserved /2007/ $15.00 DOI: / pharyngitis, suppurative complications (such as otitis media), and nonsuppurative sequelae (such as acute rheumatic fever and acute glomerulonephritis). GAS infection causes significant morbidity and mortality, with an estimated 500,000 deaths worldwide, most of which are attributable to invasive infection, acute rheumatic fever, and subsequent rheumatic heart disease [1, 2]. In the United States, the annual health care costs associated with GAS are $493 million [3]. Much of this cost is attributable to cases of pharyngitis in children. Clinical management of invasive GAS infection focuses on accurate diagnosis and timely, appropriate use Epidemiology of GAS in the US CID 2007:45 (1 October) 853
2 of antimicrobial therapy. Few effective prevention tools exist. Development of a GAS vaccine is challenging because of the vast number of emm types (1100) [4] and because of concerns of potential immunologic cross-reactivity between epitopes in the organism s M protein and human tissue proteins that could trigger acute rheumatic fever or other adverse sequelae [5, 6]. Despite these difficulties, several vaccines are in preclinical phases of testing, and a 26-valent, M protein based vaccine has successfully completed a phase 2 trial involving adults [7 9]. In the United States, a GAS vaccine is likely to be marketed on the basis of its efficacy against pharyngitis in children; however, it should also have an impact on invasive pediatric disease. Although the duration of immunity is unknown, an anamnestic response was seen in a phase 1 study of a recombinant multivalent GAS vaccine [10]. The Centers for Disease Control and Prevention (CDC) began surveillance for invasive GAS infections in 5 US sites in 1995 as part of the Active Bacterial Core surveillance (ABCs) program of the Emerging Infections Programs Network. We report the epidemiologic characteristics of invasive GAS infection in the United States for 5 years of surveillance ( ), evaluate trends in incidence over a longer time frame ( ), and estimate the potential impact of a multivalent GAS vaccine. METHODS Surveillance. We reviewed ABCs data on case patients from whom GAS-positive specimens were obtained during the period from 1 January 2000 through 31 December ABCs is active, population- and laboratory-based surveillance that tracks invasive GAS infections in 10 US sites, covering a 2004 population of 29.7 million persons ( 9.5% of the US population). ABCs methods have been described elsewhere [1, 11]. The ABCs sites (and years) included in this analysis are as follows: 3-county San Francisco Bay area, California ( ); the 5-county Denver area, Colorado (mid ); the 20- county Atlanta area, Georgia (2004); the 6-county Baltimore metropolitan area, Maryland ( ); the 3-county Portland area, Oregon ( ); the 15-county Rochester and Albany areas of New York ( ); the 11 urban county area of Tennessee ( ); and the entire states of Georgia ( ), Minnesota ( ), New Mexico (2004), and Connecticut ( ). ABCs personnel routinely contacted all participating clinical microbiology laboratories to identify cases. A case was defined as isolation of GAS from a normally sterile site or from a wound specimen obtained from a surveillance area resident with NF or STSS. Case patients who had GAS-positive blood culture results but no identified clinical syndrome were categorized as having bacteremia without a source. The remaining case patients with bacteremia were categorized as having 1 clinical syndrome. To allow comparisons with previously published data from , we categorized clinical syndromes as occurring among 2 age groups: children aged!10 years and persons aged 10 years [1]. Case patients who had undergone surgery in the 7 days before their first positive culture result were considered to be recent surgery case patients. Nosocomial infections were defined as infections in case patients who were hospitalized at least 48 h before their positive culture result. Descriptive epidemiology. Descriptive analysis included all cases from 1 January 2000 through 31 December Unless otherwise specified, incidences are expressed as the number of cases per 100,000 population. We used regional and national intercensus population estimates for each year as the denominator. For national rate estimates, race- and age-specific disease rates were applied from the aggregate surveillance area to the age and racial distribution of the US population for each year. Individuals of unknown race (13%) were distributed by site on the basis of reported race distribution for known cases. Casefatality rates (CFRs) were calculated using outcomes at the time of hospital discharge. To examine incidence trends over time ( ), data were restricted to sites used in previous incidence estimates: the 8-county Atlanta area; the 7-county Minneapolis/St. Paul area; the 3-county Portland area; the 3-county San Francisco area; and all of Connecticut [1]. GAS typing. All available GAS isolates were confirmed and typed at the CDC s Streptococcus laboratory. emm Typing was performed on the basis of restriction analysis of emm gene amplicons or on the basis of sequencing of the variable M serotype specific region of emm gene amplicons. Concordance has been established between the emm type and M serotype. The protocol for emm typing and a complete, downloadable listing of emm type sequences are available online [4, 12]. Estimates of vaccine benefit. To estimate the potential benefits of a multivalent vaccine, we used available emm typing results to calculate the proportion of disease cases and deaths due to GAS emm types in the proposed 26-valent vaccine (types 1, 1.2, 2, 3, 5, 6, 11, 12, 14, 18, 19, 22, 24, 28, 29, 33, 43, 59, 75, 76, 77, 89, 92, 94, 101, and 114) for age groups at highest risk of developing invasive GAS disease: children aged!5 years and adults aged 65 years. We hypothesized that the vaccine efficacy rate would be 84% on the basis of averaged seroconversion rates from immunogenicity (phase I/II) studies among healthy adults [7, 9, 13], and we hypothesized that vaccine coverage rates would be 70% 90% for infants (on the basis of Haemophilus influenzae type b and pneumococcal vaccination rates [14]) and 60% 70% for adults 65 years (on the basis of influenza and pneumococcus vaccination rates [15]). We used the following formula to calculate the number of GAS cases and deaths that could potentially be prevented with a 854 CID 2007:45 (1 October) O Loughlin et al.
3 GAS vaccine: efficacy (%) coverage (%) the percentage of vaccine emm types in the 26-valent vaccine. Predictors of death. We evaluated predictors of death using a conditional logistic regression model stratified by ABCs site. Case patients with multiple clinical syndromes were classified in the category of highest severity on the basis of the CFR for each syndrome. In addition, cutaneous and soft-tissue infections were included as one syndrome. Underlying illnesses were grouped into the following 4 categories: no underlying illness, skin condition (e.g., burns, varicella, and wounds), chronic illness (e.g., diabetes and chronic obstructive pulmonary disease), and immunosuppression (e.g., AIDS and asplenia). A person with multiple underlying illnesses was placed in the category of highest severity on the basis of the following decreasing levels of severity: immunosuppression, chronic illness, and skin condition. The model included only case patients for whom information on all variables was available. One site that did not record information on HIV/AIDS status was excluded, as were case patients with unknown ( n p 148) or nontypable ( n p 1) emm types or with unknown outcomes ( n p 32). Var- iables associated with death ( P!.1) on univariate analysis were entered in the multivariable model and were retained if the P value was!.05. Collinearity and all 2-way interactions were evaluated. All analyses were conducted using SAS software, version 9.1 (SAS Institute). RESULTS Demographic characteristics and disease rates. ABCs identified 5400 cases of invasive GAS infection during the period from 1 January 2000 through 31 December The median age of case patients was 50 years (range, years); 53% were male ( n p 2845). The majority of patients were white (3307 patients [61%]), with black patients (1093 patients [20%]), Asian or American Indian patients (215 patients [4%]), patient of other race (93 patients [2%]), and patients with unknown race (692 patients [13%]) making up the remainder. The distribution of unknown race varied by site, ranging from 1% in Maryland to 38% in New Mexico. The average annual incidence for the 5 years of surveillance was 3.5 invasive GAS cases per 100,000 persons (table 1). Incidence varied by site, ranging from 2.0 to 5.9 cases per 100,000 persons in Georgia and Colorado, respectively, and most sites had slight year-to-year variation. Rates for sites where data were available over a continuous 9-year period showed no significant trend (1996, 3.5 cases per 100,000 persons; 1997, 3.6 cases per 100,000 persons; 1998, 3.5 cases per 100,000 persons; 1999, 3.5 cases per 100,000 persons; 2000, 3.7 cases per 100,000 persons; 2001, 3.7 cases per 100,000 persons; 2002, 3.1 cases per 100,000 persons; 2003, 4.0 cases per 100,000 persons; and 2004, 3.0 cases per 100,000 persons; P p.2). Seasonal variation was observed, with most disease occurring in the winter and early Table 1. Incidence of invasive group A streptococcal disease, by site and year, Active Bacterial Core Surveillance (ABCs), ABCs site Year of surveillance (n p 5238) year average a California Colorado Connecticut Georgia b Maryland Minnesota New Mexico New York Oregon Tennessee All sites Estimated United States c NOTE. Data are no. of cases per 100,000 persons. a The 4-year average is shown for Colorado, and the 1-year incidence is shown for New Mexico. b Includes the entire state of Georgia for and 20 metropolitan counties for c Race- and age-specific rates of disease were applied from the aggregate surveillance area to the age and racial distribution of the US population for each year. spring; this same pattern was noted by syndrome and site, with minor variations. Incidences were highest among patients aged 65 years (9.4 cases per 100,000 persons), followed by children aged!1 year (5.3 cases per 100,000 persons) (figure 1). The incidence was also significantly higher among black patients (4.7 cases per 100,000 persons) than among nonblack patients (3.2 cases per 100,000 persons; OR, 1.5; 95% CI, ). The majority of case patients were hospitalized (4915 patients [91%]), and 734 died (CFR, 13.7%). Compared with hospitalized patients, case patients who were not hospitalized presented more frequently with bacteremia (51% vs. 27%; P!.001) and less frequently with cellulitis (20% vs. 38%; P!.001). The outcome was unknown for 32 case patients (0.6%). The CFR was highest in the oldest age group (22.8%) and was lower among black patients (12.1%) than among nonblack patients (14.1%), although this difference was not significant (OR, 0.9; 95% CI, ). Projecting to the US population, with adjustment for race and age, we estimate that ,500 invasive GAS infections occurred in the United States annually, resulting in deaths. Underlying disease. Underlying disease status was available for 5151 patients (95%); 67% had at least 1 underlying condition, and 35% had at least 2. The most common underlying conditions and definitions are shown in table 2 and include heart disease, diabetes mellitus, and skin conditions. For most conditions, there was significant variation across sites, with the Epidemiology of GAS in the US CID 2007:45 (1 October) 855
4 Figure 1. Incidence of invasive group A streptococcal disease at 10 Active Bacterial Core Surveillance sites, by age and race, Numbers are incidence rates by age group for all races combined. Age-specific case-fatality rates (CFRs) for all races combined are indicated by the black line. greatest variation noted for alcohol abuse, injection drug use, and skin conditions. There was no significant association between race and underlying condition (OR, 0.9; 95% CI, ). Case patients aged!10 years were significantly less likely to have an underlying disease (22%) than were those aged 10 years (72%; P!.001). Clinical syndromes. The distribution of clinical syndromes, by age group and CFR (with and without additional syndromes), is presented in table 3. More than one-third (36%) of case patients presented with a cutaneous or soft-tissue infection, 29% presented with primary bacteremia, and 15% presented with pneumonia. Compared with case patients aged 10 years, those aged!10 years were significantly less likely to present with a cutaneous or soft-tissue infection, NF, or endocarditis/pericarditis and were more likely to present with abscesses, osteomyelitis, epiglotitis/otitis media, meningitis, or primary bacteremia. Case patients with STSS, meningitis, NF, or pneumonia had the highest CFRs. Among case patients for whom the information was available (94%), 188 (4%) had recently undergone surgery, 118 (2.6%) were pregnant or had recently given birth, and 275 (6%) had nosocomially acquired infection. The distribution of clinical syndromes was similar among case patients with and without nosocomially acquired infections. GAS was most frequently isolated from blood specimens (4131 patients [77%]). Other sources included joint fluid (8%), surgical specimens (6%), peritoneal fluid (2%), pleural fluid (2%), and wounds (2%). Other sources each accounted for 1% of cases. emm Sequence types and potential vaccine-preventable disease. A bacterial isolate was available for typing for 4350 case patients (81%); only 1 isolate was nontypable. Distribution of emm types varied by ABCs site and by year. The 30 most common emm types accounted for 95% of isolates (figure 2). emm Types 1 (22%), 3 (9%), 28 (9%), 12 (9%), and 89 (6%) were the most common and cumulatively accounted for 55% of isolates. The 26 most common emm types accounted for 93% of isolates, whereas emm types in the proposed 26-valent vaccine (which includes M types historically associated with acute rheumatic fever) accounted for 79% of all isolates; 85% and 88% of NF and STSS isolates, respectively; and 79% of isolates in patients who died. The proportion of disease accounted for by emm types in the proposed vaccine varied little over 10 years of surveillance (82%, 83%, 81%, 81%, 77%, 74%, 79%, 83%, 81%, and 76% for each year during , respectively) and was similar among children aged!5 years (83%) and adults aged 65 years (85%). When the efficacy and coverage estimates described earlier were applied, a 26- valent vaccine could potentially prevent 49% 63% of invasive GAS infections among children and 43% 50% of cases among elderly persons, with similar decreases in the number of deaths (table 4). Predictors of death. Increasing age, residence in a nursing 856 CID 2007:45 (1 October) O Loughlin et al.
5 Table 2. Underlying conditions reported among case patients with invasive group A streptococcal disease by surveillance area, Active Bacterial Core Surveillance site Underlying condition a California (n p 685) Colorado b (n p 516) Connecticut (n p 635) Georgia b (n p 757) Maryland (n p 728) Minnesota (n p 742) New Mexico b (n p 88) New York (n p 362) Oregon (n p 225) Tennessee (n p 413) Total (n p 5151) P c Heart disease d 109 (15.9) e 76 (14.7) e 150 (23.6) e 145 (19.2) 136 (18.7) 139 (18.7) 14 (15.9) 106 (29.3) e 52 (23.1) 125 (30.3) e 1052 (20.4) Diabetes mellitus 127 (18.6) 96 (18.6) 146 (23.0) e 140 (18.5) 151 (20.7) 140 (18.9) 19 (21.6) 78 (21.6) 35 (15.6) 103 (24.9) e 1035 (20.1)!.05 Alcohol abuse 129 (18.8) e 117 (22.7) e 52 (8.2) e 47 (6.2) e 71 (9.8) 64 (8.6) e 15 (17.1) 24 (6.6) e 31 (13.8) 22 (5.3) e 572 (11.0) Malignancy f 56 (8.2) e 48 (9.3) 71 (11.2) 90 (11.9) 64 (8.8) 102 (13.8) e 9 (10.2) 49 (13.5) 30 (13.3) 29 (7.0) e 548 (10.7)!.01 Injection drug use 118 (17.2) e 29 (5.6) 40 (6.3) e 12 (1.6) e 161 (22.1) e 11 (1.5) e 6 (6.8) 7 (1.9) e 35 (15.6) e 8 (1.9) e 427 (8.3) Emphysema and/or COPD 50 (7.3) 51 (9.9) e 62 (9.8) e 53 (7.0) 61 (8.4) 43 (5.8) e 6 (6.9) 23 (6.4) 21 (9.3) 25 (6.1) 395 (7.7)!.07 Immunosuppression g 33 (4.8) e 41 (8.0) 60 (9.5) e 53 (7.0) 56 (7.7) 62 (8.4) 5 (5.7) 32 (8.8) 12 (5.3) 17 (4.1) e 371 (7.2)!.01 Renal failure/dialysis 46 (6.7) 28 (5.4) 38 (6.0) 58 (7.7) 37 (5.1) e 53 (7.1) 8 (9.1) 33 (9.1) 8 (3.6) e 43 (10.4) e 352 (6.8)!.01 Skin condition h 104 (15.2) 113 (22.0) e 64 (10.1) e 138 (18.2) 159 (21.8) e 147 (19.8) e 22 (25.0) e 23 (6.4) e 56 (24.9) e 50 (12.1) e 876 (17.0) No underlying illness 214 (31.2) 117 (22.7) e 249 (39.2) e 286 (37.8) e 206 (28.3) e 268 (36.1) 23 (26.1) 125 (34.5) 65 (28.9) 150 (36.3) 1703 (33.1) 11 Underlying illness i 277 (40.4) e 183 (35.5) 237 (37.3) 230 (30.4) e 329 (45.2) e 227 (37.3) e 34 (38.7) 116 (32.0) 93 (36.5) 131 (31.7) 1857 (36.1) NOTE. Data are no. (%) of underlying conditions, unless otherwise indicated. COPD, chronic obstructive pulmonary disease. a Some patients had 11 underlying condition. The underlying condition was unknown for 249 case patients (4.6%). Those conditions that totaled!5% of cases are not presented here and include cerebrovascular accident (4.1%), HIV infection/aids (3.2%), cirrhosis/liver failure (2.7%), and asplenia/sickle cell disease (0.8%). c e b Colorado data are from mid-2000 through 2004; for Georgia, data are for the entire state for and for 20 metropolitan counties for 2004; New Mexico data are for 2004 only. Variation in the proportion of each underlying condition across all sites; determined by x 2 test. d Includes heart failure or atherosclerotic cardiovascular disease. P!.05 for all; the P value indicates the variation across sites when each site was compared with the remaining sites combined. Includes leukemia, myeloma, Hodgkin disease, or other malignancies. g Resulting from immunoglobulin deficiency, treatment of systemic lupus erythematosus, nephrotic syndrome, organ transplantation, or receipt of immunosuppressive therapy. h Includes burns, varicella, blunt or penetrating trauma, and surgical wounds. Data are no. (%) of case patients who have 11 underlying condition; denominator is the total no. of patients with an underlying condition, by site. f i
6 Table 3. Clinical syndromes and case-fatality rates (CFRs) among case patients with invasive group A streptococcal (GAS) disease, by age group, Syndrome a All (n p 5400) Case patient group Patients aged!10 years (n p 572) b Patients aged 10 years (n p 4826) b Cutaneous and/or soft-tissue infection d No. (%) of case patients 1947 (36.4) 124 (21.7) 1823 (37.7) CFR, % (CFR when only the specified syndrome was present, %) 8.0 (6.8) 0 (0) 8.5 (7.2) Bacteremia without a source No. (%) of case patients 1586 (29.4) 204 (35.7) 1382 (28.6) CFR, % (CFR when only the specified syndrome was present, %) 16.7 (17.0) 3.4 (3.6) 18.5 (19.0) Pneumonia.26 No. (%) of case patients 792 (14.7) 93 (16.3) 699 (14.5) CFR, % (CFR when only the specified syndrome was present, %) 22.9 (23.0) 11.8 (10.7) 24.3 (24.7) Septic arthritis.7 No. (%) of case patients 416 (7.7) 47 (8.9) 369 (8.5) CFR, % (CFR when only the specified syndrome was present, %) 2.7 (2.2) 0 (0) 3.0 (2.5) Necrotizing fasciitis e No. (%) of case patients 389 (7.2) 5 (0.9) 384 (8.0) CFR, % (CFR when only the specified syndrome was present, %) 23.7 (25.4) 20.0 (33.3) 23.7 (25.3) Streptococcal toxic shock syndrome e.20 No. (%) of case patients 309 (5.7) 26 (4.6) 283 (5.9) CFR, % (CFR when only the specified syndrome was present, %) 35.9 (43.2) 7.7 (7.1) 38.5 (49.4) Abscess No. (%) of case patients 329 (6.1) 57 (9.9) 272 (5.6) CFR, % (CFR when only the specified syndrome was present, %) 4.0 (3.6) 0 (0) 4.8 (4.6) Abdominal and/or peritoneal infection.59 No. (%) of case patients 152 (2.8) 18 (3.2) 134 (2.8) CFR, % (CFR when only the specified syndrome was present, %) 12.6 (12.2) 11.1 (7.7) 12.7 (12.9) Osteomyelitis No. (%) of case patients 186 (3.4) 34 (5.9) 152 (3.2) CFR, % (CFR when only the specified syndrome was present, %) 1.1 (0) 0 (0) 1.3 (0) Pregnancy-related infection f NA No. (%) of case patients 57 (1.1) NA 57 (1.2) CFR, % (CFR when only the specified syndrome was present, %) 7.1 (4.3) NA 7.1 (4.3) Endocarditis and/or pericarditis!.01 No. (%) of case patients 75 (1.4) 1 (0.2) 74 (1.5) CFR, % (CFR when only the specified syndrome was present, %) 4.0 (6.1) 0 (0) 4.1 (6.3) Meningitis and/or CNS infection No. (%) of case patients 52 (1.0) 17 (3.0) 35 (0.7) CFR, % (CFR when only the specified syndrome was present, %) 26.9 (17.1) 23.5 (18.2) 28.6 (16.7) Epiglottitis and/or otitis media No. (%) of case patients 72 (1.3) 22 (3.9) 50 (1.0) CFR, % (CFR when only the specified syndrome was present, %) 12.5 (5.9) 4.6 (0) 16.0 (8.1) Other g.003 No. (%) of case patients 29 (0.5) 8 (1.4) 21 (0.4) CFR, % (CFR when only the specified syndrome was present, %) 3.5 (0) 0 (0) 4.8 (0) NOTE. NA, not applicable. a Case patients may have had 11 syndrome, with the exception of bacteremia without a source. Clinical syndromes, such as cutaneous and/ or soft-tissue infection and pneumonia, had to be accompanied by recovery of an isolate from a normally sterile site or specimen, such as blood, to meet case definition. b The ages for 2 case patients were missing. c Comparison by age category of the proportion of invasive GAS infections attributable to a particular syndrome; determined by x 2 test. d Includes cellulitis ( n p 1838), infected ulcers, erisypelas, wound infections, phlebitis including thrombophlebitis, lymphangitis, lymphadenitis, bursitis without a GAS-positive joint fluid culture, and gangrene; excludes necrotizing fasciitis. e Sixty-two case patients (1.2%) presented with both streptococcal toxic shock syndrome and necrotizing fasciitis (combined CFR, 35.5%). f Includes endometritis ( n p 38), septic abortion ( n p 6), chorioamnionitis ( n p 6), and puerperal sepsis ( n p 11). g Other includes hemolytic uremic syndrome ( n p 2) and unknown syndromes ( n p 27). P c
7 Figure 2. Cumulative frequency of the 30 most common emm types, Active Bacterial Core Surveillance data, Black bars indicate the emm types included in the proposed 26-valent vaccine, and white bars indicate the emm types that are not included. Other 26-valent vaccine emm types constituted 1.2% of the total, and other non 26-valent vaccine emm types constituted 3.9% of the total. home, and presence of a specific disease syndrome (i.e., STSS, meningitis, NF, pneumonia, or bacteremia), emm type (1, 3, or 12), or underlying condition (i.e., skin condition, chronic illness, or immunosuppression) were all independent predictors of an increased risk of death (table 5). Male sex was an independent predictor of a reduced risk of death. No statistically significant 2-way interactions were found. DISCUSSION Invasive GAS infection is a significant cause of morbidity and mortality in the United States, with ,500 episodes and deaths each year. The rates of disease are highest among children aged!1 year and persons aged 65 years. Because 91% of case patients are hospitalized, invasive GAS infection also places a significant burden on the health care system. No other data source in the United States provides such an extensive, current description of the frequency of severe disease manifestations of this pathogen. Our findings help address recurrent concerns among health care providers, epidemiologists, and sometimes the general public regarding perceived increases in deadly manifestations of severe GAS infections in the United States. Although rates vary among smaller communities, our study found that the incidence and mortality rate of invasive GAS infections in the United States have remained relatively stable from 1996 to The overall incidence of 3.5 cases per 100,000 persons is consistent with rates found in Canada (3.8 cases per 100,000 persons) [16] and several European countries, including The Netherlands (3.1 cases per 100,000 persons), Norway (3.3 cases per 100,000 persons), and the United Kingdom ( cases per 100,000 persons) [17]. This relative stability in disease incidence contrasts with the epidemiology of invasive GAS disease in the 1980s and early 1990s, when reports from the United States suggested an increasing severity of infection, accompanied by a potential concurrent increase in incidence [18, 19], although this increase was difficult to confirm because of the limited population-based longitudinal surveillance. Invasive GAS infection rates varied both among geographically disparate ABCs sites and within sites over time. Such inter- and intrasite variations have been found previously in the United States [1], Canada [16], and Europe [17] and can be attributed partially to differences found in circulating emm types and in the population s susceptibility to a particular emm type over time. Variations may also be due to site-to-site differences in the prevalence of risk factors for invasive GAS infection, including chronic diseases (e.g., HIV infection, diabetes, cardiac disease, cancer, and substance abuse), race, and number of persons living in the home [20, 21]. In our study, rates of underlying medical conditions in particular, those related to behaviors such as alcohol and drug abuse varied widely between sites. Epidemiology of GAS in the US CID 2007:45 (1 October) 859
8 Table 4. Calculation of potential invasive group A streptococcal (GAS) disease and fatalities prevented by vaccination of infants and elderly persons with a proposed 26-valent vaccine. Age group Children aged!5 years (n p 295) b Assumed vaccine efficacy, % (A) Assumed vaccine coverage, % (B) Case patients with GAS disease due to 26-valent emm type, % a (C) GAS-related deaths associated with a 26-valent emm type, % a (D) Potential cases of disease prevented, %(A B C) Potential deaths prevented, %(A B D) Low coverage assumption High coverage assumption Adults aged 65 years (n p 1368) b Low coverage assumption High coverage assumption NOTE. Proposed 26-valent vaccine from [7]. a Among patients with a typed isolate. b The n value represents the number of patients with an isolate available. The rate of invasive GAS infection among all children aged!5 years was 3.4 cases per 100,000 persons, and the rate among all adults aged 65 years was 9.4 cases per 100,000 persons. Although stable over time, rates of invasive GAS infection measured by ABCs are likely minimum estimates, because ABCs does not capture invasive infections without sterile site isolates unless they are manifested by STSS and NF. A previous study compared the number of patients with STSS and/or NF reported via standard ABCs methods with the number identified through comprehensive chart review, with subsequent reclassification of patients with STSS or NF according to required clinical and laboratory criteria. Patients with invasive infection presented with STSS and NF at least twice as frequently as recognized by standard ABCs methods [22]. We kept our methods similar to those of the analysis to allow direct comparisons [1]. Significant differences include additional variables in the predictors of death model (i.e., nursing home, underlying illness, and sex); a new syndrome consisting of epiglottitis and otitis media, which were previously classified under the category of other syndrome; an expanded definition of the underlying condition termed skin to include blunt or penetrating trauma and surgical wounds data not previously collected; and a change in definition of nosocomial infection (reduced from 3 to 2 days after hospital admission to the date of culture positivity). Identification of factors associated with mortality can guide disease-prevention efforts. Vaccines developed to prevent invasive GAS infections should include emm types 1, 3, and 12. The increased risk of death among the elderly, persons with certain underlying diseases, and those residing in a nursing home highlights the importance of following infection control guidelines for long-term care facilities and suggests a potential target population for immunization should a GAS vaccine be shown to be effective in the elderly and licensed for use for this age group. We are unable to explain the apparent protective effect of being male and acknowledge that there may be confounders for which we were unable to control. Current strategies for preventing morbidity and mortality resulting from invasive GAS infections are limited to promoting routine infection control, healthy behaviors and practices, and preventing secondary cases among postpartum and postsurgical patients [23]. We estimate that a proposed 26-valent GAS vaccine could prevent 40% 50% of cases and 50% 60% of deaths due to invasive GAS infections among children and elderly persons, respectively, in the United States. These may be overestimates, because we assumed vaccination of both infants and the elderly, used immunogenicity data from healthy adults, which may not be an adequate proxy for vaccine efficacy, and used coverage estimates based on other vaccines. However, our estimates also do not include a possible benefit resulting from herd immunity. Stability of the distribution of emm types over time is essential for successful prevention by vaccination. Although invasive infections comprise only a small proportion of the total burden of GAS disease, they include a significant proportion of GAS-associated morbidity and mortality in the United States. In industrialized countries, the development and introduction of a GAS vaccine is likely to be driven by the burden of noninvasive disease specifically, pharyngitis in children. The proposed 26-valent GAS vaccine includes immunogens for 86% of GAS isolates obtained from acute pharyngitis surveillance in the United States [24]. Nonsuppurative sequelae, such as acute rheumatic fever, may also be prevented by a GAS vaccine. The limited information available from developing and middle-income countries on the distribution of emm and clonal types, for both invasive and noninvasive GAS disease, show increased diversity and different emm types, compared with distribution in the United States [25 28]. 860 CID 2007:45 (1 October) O Loughlin et al.
9 Table 5. Results of multivariable analysis of factors independently associated with death due to invasive group A streptococcal disease for cases (n p 3974) reported from 1 January 2000 through 31 December 2004, stratified by Active Bacterial Core Surveillance site. Variable OR (95% CI) Age, years!18 Reference ( ) ( ) ( ) Race Nonblack Reference Black 0.9 ( ) Sex Female Reference Male 0.7 ( ) Nursing home residence No Reference Yes 1.9 ( ) Syndrome a Syndrome other than those listed below Reference Streptococcal toxic shock syndrome 12.7 ( ) Necrotizing fasciitis 5.3 ( ) Pneumonia 2.9 ( ) Bacteremia without a source 2.8 ( ) Meningitis and/or CNS infection 8.0 ( ) Cutaneous and/or soft-tissue infection 0.8 ( ) emm Type Not emm1, emm3, or emm12 Reference emm1 1.9 ( ) emm3 2.2 ( ) emm ( ) Health status No underlying illness Reference Skin condition a 1.4 ( ) Chronic illness 1.6 ( ) Immunosuppression 2.2 ( ) NOTE. Data from New York were excluded, because deaths were associated with HIV infection/aids were not reported. a Includes burns, varicella, and wounds. Rapid advances in vaccine technology, particularly the possibility of a protein-based vaccine that may eliminate the need for multivalent conjugate preparations, are promising [24]. Meanwhile, continued surveillance is essential to document disease burden, monitor changes in emm distribution, guide public health prevention activities, identify target populations for vaccination, and provide data for vaccine cost-benefit analyses. The World Health Organization has plans to develop international standards for GAS surveillance, to generate disease burden estimates in multiple countries. This will be important to guide design of vaccines that could have global utility. Acknowledgments We thank the following Emerging Infections Programs staff members: Pam Daily (California); Steve Burnite, Allison Daniels, Nicole Haubert, Joyce Knutsen, and Karen Xavier (Colorado); James Hadler, Susan Petit, and M. Zachariah Fraser (Connecticut); Kathryn E. Arnold and Wendy Baughman (Georgia); Laurie Thomson Sanza (Maryland); Jean Rainbow, Brenda Jewell, and Richard Danila (Minnesota); Joseph Bareta, Kathy Angeles, Lisa Butler, Joanne Keefe, and Karen Johnson (New Mexico); Glenda Smith and Nellie Dumas (New York); Karen Stefonek, Margaret Dragoon, and Anna Zeigler (Oregon); and Brenda Barnes and William Schaffner (Tennessee). We also thank Tami Skoff, Carolyn Wright, and Elizabeth Zell (of the CDC s ABCs program) and Varja Sakota, Zhongya Li, Delois Jackson, and Alma Ruth Franklin (of the CDC s Streptococcus laboratory). In addition, we thank Kate O Brien (Johns Hopkins Bloomberg School of Public Health). Financial support. Support for the ABCs is provided by the CDC s Emerging Infections Programs. Potential conflicts of interest. All authors: no conflicts. References 1. O Brien KL, Beall B, Barrett NL, et al. Epidemiology of invasive group A streptococcus disease in the United States, Clin Infect Dis 2002; 35: Department of Child and Adolescent Health and Development, Department of Immunization Vaccines and Biologicals. The current evidence for the burden of group A streptococcal diseases. Geneva: World Health Organization, Institute of Medicine. In: Stratton KR, ed. Vaccines for the 21st century. Washington, DC: National Academy Press, 2001: Streptococcus pyogenes emm sequence database. Available at: wwwcdcgov/ncidod/biotech/strep/strepblasthtm. Accessed 22 May Bisno AL, Rubin FA, Cleary PP, Dale JB. Prospects for a group A streptococcal vaccine: rationale, feasibility, and obstacles--report of a National Institute of Allergy and Infectious Diseases workshop. Clin Infect Dis 2005; 41: Department of Child and Adolescent Health and Development, Department of Immunization Vaccines and Biologicals Group. Group A streptococcal vaccine development: current status and issues of relevance to less developed countries. WHO/IVB/ Geneva: World Health Organization, McNeil SA, Halperin SA, Langley JM, et al. Safety and immunogenicity of 26-valent group A Streptococcus vaccine in healthy adult volunteers. Clin Infect Dis 2005; 41: Hu MC, Walls MA, Stroop SD, Reddish MA, Beall B, Dale JB. Immunogenicity of a 26-valent group A streptococcal vaccine. Infect Immun 2002; 70: McMillan D. StreptAvax (ID Biomedical). Curr Opin Investig Drugs 2006; 7: Kotloff KL, Dale JB. Progress in group A streptococcal vaccine development. Pediatr Infect Dis J 2004; 23: Active Bacterial Core surveillance methodology. Available at: Accessed 22 May CDC s Protocol for emm typing. Available at: Accessed 22 May Kotloff KL, Corretti M, Palmer K, et al. Safety and immunogenicity of a recombinant multivalent group a streptococcal vaccine in healthy adults: phase 1 trial. JAMA 2004; 292: Estimated vaccination coverage with individual vaccines and selected vaccination series among children months of age by state USNIS, Available at: antigen_state.xls. Accessed 22 May Influenza and pneumococcal vaccination coverage among persons aged Epidemiology of GAS in the US CID 2007:45 (1 October) 861
10 65 years and persons aged years with diabetes or asthma United States, MMWR Morb Mortal Wkly Rep 2004; 53: Tyrrell GJ, Lovgren M, Kress B, Grimsrud K. Invasive group A streptococcal disease in Alberta, Canada (2000 to 2002). J Clin Microbiol 2005; 43: Lamagni T, Efstratiou A, Vuopio-Varkila J, Jasir A, Schalen C. The epidemiology of severe Streptococcus pyogenes associated disease in Europe. Euro Surveill 2005; 10: O Brien KL, Levine OS, Schwartz B. The changing epidemiology of group A streptococcus infections. Semin Pediatr Infect Dis 1997;8: Givner LB, Abramson JS, Wasilauskas B. Apparent increase in the incidence of invasive group A beta-hemolytic streptococcal disease in children. J Pediatr 1991; 118: Factor SH, Levine OS, Schwartz B, et al. Invasive group A streptococcal disease: risk factors for adults. Emerg Infect Dis 2003; 9: Factor SH, Levine OS, Harrison LH, et al. Risk factors for pediatric invasive group A streptococcal disease. Emerg Infect Dis 2005; 11: Cowgill KD, Van Beneden C, Wright C, Beall B, Schuchat A; the Active Bacterial Core Surveillance Team. Burden of streptococcal toxic shock syndrome and necrotizing fasciitis United States, 2002 [abstract 238]. In: Program and abstracts of the 43rd Annual Meeting of the Infectious Diseases Society of American (San Diego, California). Alexandria, VA: Infectious Diseases Society of America, 2003: Prevention of Invasive Group A Streptococcal Infections Workshop Participants. Prevention of invasive group A streptococcal disease among household contacts of case patients and among postpartum and postsurgical patients: recommendations from the Centers for Disease Control and Prevention. Clin Infect Dis 2002; 35:950 9 (erratum: Clin Infect Dis 2003; 36:243). 24. Shulman ST, Tanz RR, Kabat W, et al. Group A streptococcal pharyngitis serotype surveillance in North America, Clin Infect Dis 2004; 39: Teixeira LM, Barros RR, Castro AC, et al. Genetic and phenotypic features of Streptococcus pyogenes strains isolated in Brazil that harbor new emm sequences. J Clin Microbiol 2001; 39: Lopardo HA, Vidal P, Sparo M, et al. Six-month multicenter study on invasive infections due to Streptococcus pyogenes and Streptococcus dysgalactiae subsp. equisimilis in Argentina. J Clin Microbiol 2005; 43: Dey N, McMillan DJ, Yarwood PJ, et al. High diversity of group A streptococcal emm types in an Indian community: the need to tailor multivalent vaccines. Clin Infect Dis 2005; 40: Abdissa A, Asrat D, Kronvall G, et al. High diversity of group A streptococcal emm types among healthy schoolchildren in Ethiopia. Clin Infect Dis 2006; 42: CID 2007:45 (1 October) O Loughlin et al.
Invasive Bacterial Disease
Invasive Bacterial Disease Neisseria meningitidis, Haemophilus influenzae, and Group B Streptococcus (Streptococcus agalactiae) Case Report Form Electronic Disease Surveillance System Division of Surveillance
More informationInvasive Bacterial Disease
Invasive Bacterial Disease All Streptococcus pneumoniae Electronic Disease Surveillance System Division of Surveillance and Disease Control Infectious Disease Epidemiology Program : 304-558-5358 or 800-423-1271
More informationHaemophilus influenzae Surveillance Report 2012 Oregon Active Bacterial Core Surveillance (ABCs) Center for Public Health Practice Updated: July 2014
Haemophilus influenzae Surveillance Report 2012 Oregon Active Bacterial Core Surveillance (ABCs) Center for Public Health Practice Updated: July 2014 Background The Active Bacterial Core surveillance (ABCs)
More informationOf 142 cases where sex was known, 56 percent were male; of 127cases where race was known, 90 percent were white, 4 percent were
Group B Streptococcus Surveillance Report 2014 Oregon Active Bacterial Core Surveillance (ABCs) Center for Public Health Practice Updated: November 2015 Background The Active Bacterial Core surveillance
More informationIncidence per 100,
Group B Streptococcus Surveillance Report 2005 Oregon Active Bacterial Core Surveillance (ABCs) Office of Disease Prevention & Epidemiology Oregon Department of Human Services Updated: January 2007 Background
More informationIncidence per 100,000
Streptococcus pneumoniae Surveillance Report 2005 Oregon Active Bacterial Core Surveillance (ABCs) Office of Disease Prevention & Epidemiology Oregon Department of Human Services Updated: March 2007 Background
More informationImpacto de la vacuna conjugada en EUA
Impacto de la vacuna conjugada en EUA Richard Facklam, PhD, Distinguished Consultant, Retired, Centers for Disease Control and Prevention Atlanta, GA Bogotá, Colombia, February 2008 Pneumococcal Conjugate
More informationImpact of pneumococcal conjugate vaccine: US experience Stephanie Schrag Centers for Disease Control and Prevention Atlanta, GA
Impact of pneumococcal conjugate vaccine: US experience Stephanie Schrag Centers for Disease Control and Prevention Atlanta, GA San Jose, Costa Rica, August 2007 Pneumococcal Conjugate Vaccine Introduction
More informationEpidemiology of Invasive Group A Streptococcal Infections in the United States,
Clinical Infectious Diseases MAJOR ARTICLE Epidemiology of Invasive Group A Streptococcal Infections in the United States, 2005 2012 George E. Nelson, 1,2,4 Tracy Pondo, 2 Karrie-Ann Toews, 2 Monica M.
More informationSource: Portland State University Population Research Center (
Neisseria meningitidis Surveillance Report 2009 Oregon Active Bacterial Core Surveillance (ABCs) Office of Disease Prevention & Epidemiology Oregon Health Authority Updated: June 2011 Background The Active
More informationEpidemiology of Invasive Group B Streptococcal Disease in the United States, JAMA. 2008;299(17):
ORIGINAL CONTRIBUTION Epidemiology of Invasive Group B Streptococcal Disease in the United States, 1999-2005 Christina R. Phares, PhD Ruth Lynfield, MD Monica M. Farley, MD et Mohle-Boetani, MD Lee H.
More informationMethicillin-Resistant Staphylococcus aureus (MRSA) S urveillance Report 2008 Background Methods
Methicillin-Resistant Staphylococcus aureus (MRSA) Surveillance Report 2008 Oregon Active Bacterial Core Surveillance (ABCs) Office of Disease Prevention & Epidemiology Oregon Department of Human Services
More informationHaemophilus influenzae
Haemophilus influenzae type b Severe bacterial infection, particularly among infants During late 19th century believed to cause influenza Immunology and microbiology clarified in 1930s Haemophilus influenzae
More informationStreptococcus pneumoniae CDC
Streptococcus pneumoniae CDC Pneumococcal Disease Infection caused by the bacteria, Streptococcus pneumoniae» otitis media 20 million office visits (28-55% Strep)» pneumonia 175,000 cases annually» meningitis
More informationRisk for Severe Group A Streptococcal Disease among Patients Household Contacts - V...
Page 1 of 11 ISSN: 1080-6059 Volume 9, Number 4 April 2003 Research Risk for Severe Group A Streptococcal Disease among Patients Household Contacts Katherine A. Robinson* (/eid/article/9/4/02-0369_article.htm#comment),
More informationChanging Epidemiology of Invasive Pneumococcal Disease Among Older Adults in the Era of Pediatric Pneumococcal Conjugate Vaccine
ORIGINAL CONTRIBUTION Changing Epidemiology of Invasive Pneumococcal Disease Among Older Adults in the Era of Pediatric Pneumococcal Conjugate Vaccine Catherine A. Lexau, PhD, MPH Ruth Lynfield, MD Richard
More information2.3 Invasive Group A Streptococcal Disease
2.3 Invasive Group A Streptococcal Disease Summary Total number of cases, 2015 = 107 Crude incidence rate, 2015 = 2.3 per 100,000 population Notifications In 2015, 107 cases of invasive group A streptococcal
More informationIncreased incidence of invasive group A streptococcal disease in Ireland, 2012 to 2013
Rapid communications Increased incidence of invasive group A streptococcal disease in Ireland, 212 to 213 M Meehan (meehanmary@yahoo.co.uk) 1, S Murchan 2, S Bergin 3, D O Flanagan 2, R Cunney 1,2,3 1.
More informationInvasive Bacterial Diseases in the Arctic. Tom Hennessy, MD, MPH Arctic Investigations Program October 2, 2015 Copenhagen
Invasive Bacterial Diseases in the Arctic Tom Hennessy, MD, MPH Arctic Investigations Program October 2, 2015 Copenhagen Outline Introduction to Alaska International Circumpolar Surveillance Invasive bacterial
More informationGeographic Variation in Invasive Pneumococcal Disease Following Pneumococcal Conjugate Vaccine Introduction in the United States
MAJOR ARTICLE Geographic Variation in Invasive Pneumococcal Disease Following Pneumococcal Conjugate Vaccine Introduction in the United States Jennifer B. Rosen, 1,2 Ann R. Thomas, 3 Catherine A. Lexau,
More informationNQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE
Last Updated: Version 4.4 NQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE Measure Set: Immunization Set Measure ID#: Measure Information Form Collected For: CMS Voluntary Only The Joint Commission
More informationPneumococcal vaccines
Pneumococcal vaccines Marco Aurélio Sáfadi, MD, PhD FCM da Santa Casa de São Paulo Challenges in establishing the baseline burden of disease, before implementing a vaccination program S. pneumoniae disease
More informationElements for a Public Summary
VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Rapenin (phenoxymethylpenicillin potassium) is indicated for the treatment of infections caused by penicillin-sensitive bacteria.
More informationBacterial Meningitis in the United States,
T h e n e w e ngl a nd j o u r na l o f m e dic i n e original article Bacterial Meningitis in the United States, 1998 2007 Michael C. Thigpen, M.D., Cynthia G. Whitney, M.D., M.P.H., Nancy E. Messonnier,
More informationHAEMOPHILUS INFLUENZAE INVASIVE DISEASE
23 Annual Morbidity Report HAEMOPHILUS INFLUENZAE INVASIVE DISEASE CRUDE DATA 35 Annual Incidence a LA County.37 California b. United States c.2 Age at Diagnosis Mean 4. years Median 36. years Range Birth
More informationPneumococcal Disease and Pneumococcal Vaccines
Pneumococcal Disease and Epidemiology and Prevention of - Preventable Diseases Note to presenters: Images of vaccine-preventable diseases are available from the Immunization Action Coalition website at
More informationInvasive Group A Streptococcal Disease in Alberta, Canada (2000 to 2002)
JOURNAL OF CLINICAL MICROBIOLOGY, Apr. 2005, p. 1678 1683 Vol. 43, No. 4 0095-1137/05/$08.00 0 doi:10.1128/jcm.43.4.1678 1683.2005 Copyright 2005, American Society for Microbiology. All Rights Reserved.
More informationIntroduction Invasive group A streptococcal infection (igas) occurs when Streptococcus pyogenes invades a normally
Surveillance and outbreak reports Invasive Group A Streptococcal Disease in Ireland, 2004 to 2010 J Martin (Jennifer_martin@health.gov.ie) 1, S Murchan 1, D O Flanagan 1, F Fitzpatrick 1,2 1. Health Protection
More informationjournal of medicine The new england Decline in Invasive Pneumococcal Disease after the Introduction of Protein Polysaccharide Conjugate Vaccine
The new england journal of medicine established in 1812 may 1, 2003 vol. 348 no. 18 Decline in Invasive Pneumococcal Disease after the Introduction of Protein Polysaccharide Conjugate Vaccine Cynthia G.
More informationGroup B Streptococcus
Group B Streptococcus (Invasive Disease) Infants Younger than 90 Days Old DISEASE REPORTABLE WITHIN 24 HOURS OF DIAGNOSIS Per N.J.A.C. 8:57, healthcare providers and administrators shall report by mail
More informationAlberta Health and Wellness Public Health Notifiable Disease Management Guidelines August Pneumococcal Disease, Invasive (IPD)
August 2011 Pneumococcal Disease, Invasive (IPD) Revision Dates Case Definition Reporting Requirements Remainder of the Guideline (i.e., Etiology to References sections inclusive) Case Definition August
More informationPneumococcal infection is one of. Epidemiology of Pneumococcal Disease ...PRESENTATIONS... Based on a presentation by Chris Van Beneden, MD, MPH
...PRESENTATIONS... Epidemiology of Pneumococcal Disease Based on a presentation by Chris Van Beneden, MD, MPH Presentation Summary Pneumococcus is a leading cause of pneumonia and meningitis in the United
More informationInvasive Group A Streptococcal Disease: Risk Factors for Adults
Invasive Group A Streptococcal Disease: Risk Factors for Adults Stephanie H. Factor,* Orin S. Levine, Benjamin Schwartz,* Lee H. Harrison, Monica M. Farley, Allison McGeer,# and Anne Schuchat* We conducted
More informationInfluenza-Associated Pediatric Mortality Case Report Form Form Approved OMB No
Influenza-Associated Pediatric Mortality Case Report Form Form Approved OMB No. 0920-0004 STATE USE ONLY DO NOT SEND INFORMATION IN THIS SECTION TO CDC Last Name: First Name: County: Address: City: State,
More informationEpidemiology of IGAS. Allison McGeer, MSc, MD, FRCPC Mount Sinai Hospital University of Toronto
Epidemiology of IGAS Allison McGeer, MSc, MD, FRCPC Mount Sinai Hospital University of Toronto www.microbiology.mtsinai.on.ca Epidemiology of IGAS Median age: 48 years (range 0-101) 15% children (
More informationGROUP A STREPTOCOCCUS (GAS) INVASIVE
GROUP A STREPTOCOCCUS (GAS) INVASIVE Case definition CONFIRMED CASE Laboratory confirmation of infection with or without clinical evidence of invasive disease: isolation of group A streptococcus (Streptococcus
More informationInfluenza-Associated Pediatric Deaths Case Report Form
STATE USE ONLY DO NOT SEND INFORMATION IN THIS SECTION TO CDC Form approved OMB No. 0920-0007 Last Name: First Name: County: Address: City: State, Zip: Patient Demographics 1. State: 2. County: 3. State
More informationInvasive Group A Streptococcal Disease (igas) in British Columbia 2017 Annual Summary
Invasive Group A Streptococcal Disease (igas) in British Columbia 2017 Annual Summary Background In 2016, BC experienced a higher incidence of igas than observed in 2009 through 2015, with a rate surpassing
More informationUse of 13-valent Pneumococcal Conjugate Vaccine and 23-valent Polysaccharide Vaccine in Adults with Immunocompromising Conditions
Use of 13-valent Pneumococcal Conjugate Vaccine and 23-valent Polysaccharide Vaccine in Adults with Immunocompromising Conditions Tamara Pilishvili, MPH Respiratory Diseases Branch National Center for
More informationACIP Recommendations for Pneumococcal 13-valent Conjugate and 23-valent Polysaccharide Vaccine Use among Adults
ACIP Recommendations for Pneumococcal 13-valent Conjugate and 23-valent Polysaccharide Vaccine Use among Adults National Center for Immunization & Respiratory Diseases Respiratory Diseases Branch ACIP
More informationEpidemiology of Invasive Group A Streptococcus Disease in the United States,
MAJOR ARTICLE Epidemiology of Invasive Group A Streptococcus Disease in the United States, 1995 1999 Katherine L. O Brien, 1,a Bernard Beall, 1 Nancy L. Barrett, 6 Paul R. Cieslak, 7 Arthur Reingold, 8,9
More informationOpen Forum Infectious Diseases MAJOR ARTICLE
Open Forum Infectious Diseases MAJOR ARTICLE Meningococcal Disease in Patients With Human Immunodeficiency Virus Infection: A Review of Cases Reported Through Active Surveillance in the United States,
More informationINVASIVE GROUP A STREPTOCOCCAL INFECTION IN NEW ZEALAND, 2014 AND 2015
INVASIVE GROUP A STREPTOCOCCAL INFECTION IN NEW ZEALAND, 2014 AND 2015 Authors: Tammy Hambling Yvonne Galloway Susan Jack Julie Morgan PREPARED FOR: CLIENT REPORT No: PREPARED BY: Ministry of Health FW15036
More informationGroup A Streptococcus (GAS), Invasive Disease
Group A Streptococcus (GAS), Invasive Disease Including Streptococcal Toxic Shock Syndrome (STSS) DISEASE REPORTABLE WITHIN 24 HOURS OF DIAGNOSIS Per N.J.A.C. 8:57, healthcare providers and administrators
More informationGroup A streptococcal vaccines: challenges and progress. Florian Schödel Philimmune LLC
Group A streptococcal vaccines: challenges and progress Florian Schödel Philimmune LLC Thanks to: Jonathan Carapetis, Telethon Institute for Child Health Res., West Perth, AU James Dale, Univ. Memphis
More informationUPDATE ON IMMUNIZATION GUIDELINES AND PRACTICES
DISCLOSURES UPDATE ON IMMUNIZATION GUIDELINES AND PRACTICES Nothing to disclose Kylie Mueller, Pharm.D., BCPS Clinical Specialist, Infectious Diseases Spartanburg Regional Medical Center LEARNING OBJECTIVES
More informationGroup B streptococcal infection;. Bacteremia without a focus occurs in 80-85%,. July has been recognised as Group B Strep Awareness Month,.
Group B streptococcal infection;. Bacteremia without a focus occurs in 80-85%,. July has been recognised as Group B Strep Awareness Month,. 12-10-2017 Group B streptococci are uniformly sensitive to penicillin
More informationHigh Risk Conditions and Vaccination Gaps in Invasive Pneumococcal Disease Cases in Tennessee,
High Risk Conditions and Vaccination Gaps in Invasive Pneumococcal Disease Cases in Tennessee, 2011-2016 Kinley Reed Candidate for Master of Public Health September 12, 2017 Outline Brief Introduction
More informationRecommendations for Using Pneumococcal Vaccines among Adults
Recommendations for Using Pneumococcal Vaccines among Adults AI Collaborative Webinar February 2016 Tamara Pilishvili Respiratory Diseases Branch, CDC National Center for Immunization & Respiratory Diseases
More informationIncreased incidence of invasive group A streptococcal infections in Sweden, January 2012 February 2013
Rapid communications Increased incidence of invasive group A streptococcal infections in Sweden, uary 12 February 13 J Darenberg (Jessica.Darenberg@smi.se) 1, B Henriques-Normark 1,2,3, T Lepp 1, K Tegmark-Wisell
More informationPneumococcal Vaccine Effectiveness. Steven Black, MD Center for Global Health Cincinnati Children s s Hospital Cincinnati, Ohio USA
Pneumococcal Vaccine Effectiveness Steven Black, MD Center for Global Health Cincinnati Children s s Hospital Cincinnati, Ohio USA Overview Possible effectiveness outcomes for pneumococcal vaccines Pre-licensure
More informationStreptococcus Pneumoniae
Streptococcus Pneumoniae (Invasive Pneumococcal Disease) DISEASE REPORTABLE WITHIN 24 HOURS OF DIAGNOSIS Per N.J.A.C. 8:57, healthcare providers and administrators shall report by mail or by electronic
More informationEPIREVIEW INVASIVE PNEUMOCOCCAL DISEASE, NSW, 2002
EPIREVIEW INVASIVE PNEUMOCOCCAL DISEASE, NSW, 2002 Robyn Gilmour Communicable Diseases Branch NSW Department of Health BACKGROUND Infection with the bacterium Streptococcus pneumoniae is a major cause
More informationImmunization Update: New CDC Recommendations. Blaise L. Congeni M.D. 2012
Immunization Update: New CDC Recommendations Blaise L. Congeni M.D. 2012 Polysaccharide Vaccines Vaccine Hib capsule polysaccharide PRP (polyribose ribitol phosphate) Not protective in infants
More informationBacterial diseases caused by Streptoccus pneumoniae in children
Bacterial diseases caused by Streptoccus pneumoniae in children Bactermia 85% Bacterial pneumonia 66% Bacterial meningitis 50% Otitis media 40% Paranasal sinusitis 40% 0% 10% 20% 30% 40% 50% 60% 70% 80%
More informationSustained Reductions in Invasive Pneumococcal Disease in the Era of Conjugate Vaccine
MAJOR ARTICLE Sustained Reductions in Invasive Pneumococcal Disease in the Era of Conjugate Vaccine Tamara Pilishvili, 1 Catherine Lexau, 8 Monica M. Farley, 3,4 James Hadler, 5 Lee H. Harrison, 6 Nancy
More informationEpidemiology of Infectious Complications of H1N1 Influenza Virus Infection
Epidemiology of Infectious Complications of H1N1 Influenza Virus Infection Lyn Finelli, DrPH, MS Lead, Influenza Surveillance and Outbreak Response Epidemiology and Prevention Branch Influenza Division
More informationEffect of Pneumococcal Conjugate Vaccine on Pneumococcal Meningitis
The new england journal of medicine original article Effect of Pneumococcal Conjugate Vaccine on Pneumococcal Meningitis Heather E. Hsu, M.P.H., Kathleen A. Shutt, M.S., Matthew R. Moore, M.D., M.P.H.,
More informationSupplementary Online Content
Supplementary Online Content Toyoda N, Chikwe J, Itagaki S, Gelijns AC, Adams DH, Egorova N. Trends in infective endocarditis in California and New York State, 1998-2013. JAMA. doi:10.1001/jama.2017.4287
More informationChapter 16 Pneumococcal Infection. Pneumococcal Infection. August 2015
Chapter 16 16 PPV introduced for at risk 1996 PCV7 introduced for at risk 2002 and as routine 2008 PCV13 replaced PCV7 in 2010 NOTIFIABLE In some circumstances, advice in these guidelines may differ from
More informationPrevention through vaccination
Prevention through vaccination The Science of Rheumatic Fever Surveillance and Control Feb 4, 2013 Jonathan Carapetis Telethon Institute for Child Health Research Andrew Steer Centre for International
More informationAnnual Epidemiological Report
August 2018 Annual Epidemiological Report Key Facts Streptococcus 1Pneumoniae (invasive) in Ireland, 2017 In 2017, 415 confirmed cases of invasive pneumococcal diseases (IPD) were reported in Ireland,
More informationAppendix B: Provincial Case Definitions for Reportable Diseases
Ministry of Health and Long-Term Care Infectious Diseases Protocol Appendix B: Provincial Case Definitions for Reportable Diseases Disease: Group A Streptococcal Disease, invasive (igas) Revised Group
More informationMeningococcal Update. Disclosure. Meningococal and Influenza Vaccines Update! Robert Wittler, MD Sept 12, 2014 KAAP Fall CME Meeting
1 Meningococal and Influenza Vaccines Update! Robert Wittler, MD Sept 12, 2014 KAAP Fall CME Meeting 2 Disclosure Speakers Bureau: Sanofi Pasteur Vaccines and Novartis! I do not intend to discuss an unapproved/
More informationChickenpox Death. West Virginia Electronic Disease Surveillance System
Chickenpox Death Electronic Disease Surveillance System Division of Surveillance and Disease Control Infectious Disease Epidemiology Program Phone: 304-558-5358 or 800-423-1271 in Fax: 304-558-8736 Investigation
More information9/12/2018. Pneumococcal Disease and Pneumococcal Vaccines. Streptococcus pneumoniae. Pneumococcal Disease. Adult Track. Gram-positive bacteria
Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Pneumococcal Disease and Pneumococcal Vaccines Adult Track Chapter 17 Photographs and images included
More informationArctic Council Ministerial April 2009
Arctic Council Ministerial April 2009 International Circumpolar Surveillance: Prevention and Control of Infectious Diseases Report: 1999-2008 Summary Human health is a critical component of any sustainable
More informationRecommendations for Using Pneumococcal Vaccines among Adults
Recommendations for Using Pneumococcal Vaccines among Adults AI Collaborative Webinar July 2017 Tamara Pilishvili Respiratory Diseases Branch, CDC National Center for Immunization & Respiratory Diseases
More informationHaemophilus influenzae and its invisibility cloak. Anna Strain Virology Supervisor/VPD Reference Center Coordinator June 5, 2018
Haemophilus influenzae and its invisibility cloak Anna Strain Virology Supervisor/VPD Reference Center Coordinator June 5, 2018 Haemophilus influenzae Gram negative aerobic coccobacilli Pfeiffer s Bacillus-
More informationUNIVERSITY OF CALGARY. Pneumococcal Vaccination of the Elderly During Visits to Acute Care Providers: Who Are Vaccinated? David Mark Arthur Sabapathy
UNIVERSITY OF CALGARY Pneumococcal Vaccination of the Elderly During Visits to Acute Care Providers: Who Are Vaccinated? by David Mark Arthur Sabapathy A THESIS SUBMITTED TO THE FACULTY OF GRADUATE STUDIES
More informationEvaluation of Innovative Surveillance for Drug-resistant Streptococcus pneumoniae
American Journal of Epidemiology Copyright 2001 by the Johns Hopkins University Bloomberg School of Public Health All rights reserved Vol. 154,. 11 Printed in U.S.A. Surveillance for Drug-resistant S.
More informationPopulation-Based Study of Invasive Disease Due to b-hemolytic Streptococci of Groups Other than A and B
MAJOR ARTICLE Population-Based Study of Invasive Disease Due to b-hemolytic Streptococci of Groups Other than A and B Laura N. Broyles, 1 Chris Van Beneden, 2 Bernard Beall, 2 Richard Facklam, 2 P. Lynn
More informationPertussis Epidemiology and Vaccine Impact in the United States
Pertussis Epidemiology and Vaccine Impact in the United States Stacey Martin, MSc Epidemiology Team Lead Meningitis and Vaccine Preventable Diseases Branch Centers for Disease Control and Prevention Presented
More informationPneumococcal Vaccination. Bottom Line. Gangrene from Pneumococcal Bacteremia
Vaccination MSHO Performance Improvement Project Kristin L. Nichol, MD, MPH, MBA Professor of Medicine, University of Minnesota Chief of Medicine, Minneapolis VA Medical Cente Chair, MCAI Bottom Line disease
More informationExperience with Quadrivalent Meningococcal Conjugate Vaccines (MenACWY) in Adolescent Vaccine Programs in the United States and Canada
Experience with Quadrivalent Meningococcal Conjugate Vaccines (MenACWY) in Adolescent Vaccine Programs in the United States and Canada Jessica MacNeil, MPH Epidemiologist Centers for Disease Control and
More informationRecommended Childhood Immunization Schedu...ates, January - December 2000, NP Central
Recommended Childhood Immunization Schedule United States, January - December 2000 Vaccines 1 are listed under routinely recommended ages. Solid-colored bars indicate range of recommended ages for immunization.
More informationTitle: Enhancing state-based surveillance for invasive pneumococcal disease
09-ID-06 Committee: Infectious Diseases Title: Enhancing state-based surveillance for invasive pneumococcal disease I. tatement of the Problem: Cases of invasive pneumococcal disease among children less
More informationInvasive Neonatal Group-B Streptococcus (GBS) Disease in Wisconsin,
Invasive Neonatal Group-B Streptococcus (GBS) Disease in Wisconsin, 2002-2008 2008 Hanne Nissen Bjørnsen RN, MS MPH Candidate 2010 University of Wisconsin - Madison May 7 th 2010 Streptococcus agalactiae
More informationEstimating RSV Disease Burden in the United States
Estimating RSV Disease Burden in the United States Brian Rha, MD, MSPH Medical Epidemiologist, Division of Viral Diseases Centers for Disease Control and Prevention Severe Acute Respiratory Infection Surveillance
More information...REPORTS... Epidemiology of Pneumococcal Disease/ Rationale for and Efficacy of PnC7
...REPORTS... Epidemiology of Pneumococcal Disease/ Rationale for and Efficacy of PnC7 Summary A Streptococcus pneumoniae Conjugate Vaccine Managed Care Advisory Panel was presented with information on
More information3. Rapidly recognize influenza seasons in which the impact of influenza appears to be unusually severe among children.
07-ID-14 Committee: Title: Infectious Disease Influenza-Associated Pediatric Mortality Statement of the Problem: In 2004, CSTE adopted influenza-associated pediatric mortality reporting with a provision
More informationBCG vaccine and tuberculosis
PART 2: Vaccination for special risk groups 2.1 Vaccination for Aboriginal and Torres Strait Islander people Aboriginal and Torres Strait Islander people historically had a very high burden of infectious
More informationGROUP B STREPTOCOCCAL DISEASE IN THE ERA OF INTRAPARTUM ANTIBIOTIC PROPHYLAXIS
GROUP B STREPTOCOCCAL DISEASE IN THE ERA OF INTRAPARTUM ANTIBIOTIC PROPHYLAXIS GROUP B STREPTOCOCCAL DISEASE IN THE ERA OF INTRAPARTUM ANTIBIOTIC PROPHYLAXIS STEPHANIE J. SCHRAG, D.PHIL., SARA ZYWICKI,
More informationOREGON PUBLIC HEALTH, DHS IMMUNIZATION PROTOCOL FOR PHARMACISTS. PNEUMOCOCCAL POLYSACCHARIDE VACCINE 23-Valent Vaccine
OREGON PUBLIC HEALTH, DHS IMMUNIZATION PROTOCOL FOR PHARMACISTS PNEUMOCOCCAL POLYSACCHARIDE VACCINE 23-Valent Vaccine Revisions as of 2/24/10 Pneumovax 23 should not be given concurrently with Zostavax
More informationHospital-wide Impact of Mandatory Infectious Disease Consultation on Staphylococcus aureus Septicemia
Hospital-wide Impact of Mandatory Infectious Disease Consultation on Staphylococcus aureus Septicemia Amanda Guth 1 Amy Slenker MD 1,2 1 Department of Infectious Diseases, Lehigh Valley Health Network
More informationARF & RHD Primordial and Primary Prevention
ARF & RHD Primordial and Primary Prevention Bart Currie Infectious Diseases Department, Royal Darwin Hospital Global and Tropical Health Division, Menzies Northern Territory Medical Program, Flinders &
More informationAppendix B: Provincial Case Definitions for Reportable Diseases
Infectious Diseases Protocol Appendix B: Provincial Case Definitions for Reportable Diseases Disease: Pneumococcal disease, invasive Revised December 2014 Pneumococcal disease, invasive 1.0 Provincial
More informationJon Temte, MD/PhD Chair Wisconsin Council on Immunization Practices Professor of Family Medicine and Community Health
Jon Temte, MD/PhD Chair Wisconsin Council on Immunization Practices Professor of Family Medicine and Community Health University of Wisconsin School of Medicine and Public Health Grand Rounds September
More informationVaccines for Primary Care Pneumococcal, Shingles, Pertussis
Vaccines for Primary Care Pneumococcal, Shingles, Pertussis Devang Patel, M.D. Assistant Professor Chief of Service, MICU ID Service University of Maryland School of Medicine Pneumococcal Vaccine Pneumococcal
More informationTABLE OF CONTENTS 1.0 CLINICAL INFORMATION EPIDEMIOLOGY... 2
September 2017 TABLE OF CONTENTS 1.0 CLINICAL INFORMATION... 1 2.0 EPIDEMIOLOGY... 2 3.0 CASE DEFINITIONS... 3 3.1 Case definitions for surveillance of invasive GAS disease... 3 3.2 Types of cases... 4
More informationTRENDS IN PNEUMONIA AND INFLUENZA MORBIDITY AND MORTALITY
TRENDS IN PNEUMONIA AND INFLUENZA MORBIDITY AND MORTALITY AMERICAN LUNG ASSOCIATION RESEARCH AND PROGRAM SERVICES EPIDEMIOLOGY AND STATISTICS UNIT February 2006 TABLE OF CONTENTS Trends in Pneumonia and
More informationThe authors assessed drug susceptibility patterns
Drug Resistance Among Tuberculosis Patients, 1991 and 1992 New York City, CYNTHIA R. DRIVER, RN, MPH THOMAS R. FRIEDEN, MD, MPH ALAN B. BLOCH, MD, MPH IDA M. ONORATO, MD All the authors are with the Division
More informationPNEUMONIA : PROMISE FULFILLED? Regina Berba MD FPSMID
PNEUMONIA : PROMISE FULFILLED? Regina Berba MD FPSMID Objectives of Lecture Know the quality of current evidence based guidelines on immunization Appreciate the performance of pneumonia vaccines in terns
More informationThe cost of hospital care for management of invasive group A streptococcal infections in England
Epidemiol. Infect., Page 1 of 12. Cambridge University Press 2014 doi:10.1017/s0950268814002489 The cost of hospital care for management of invasive group A streptococcal infections in England G. J. HUGHES
More informationDeveloping a novel Group B Streptococcus (GBS) Vaccine. Patrick Tippoo
Developing a novel Group B Streptococcus (GBS) Vaccine Patrick Tippoo Presentation 1. Overview of Biovac 2. GBS Project Overview 3. African Significance Biovac Overview A Centre of Excellence rooted in
More informationInfectious Diseases, Chronic Diseases District of Columbia Department of Health, Center for Policy, Planning & Evaluation Assignment Description
Infectious Diseases, Chronic Diseases District of Columbia Department of Health, Center for Policy, Planning & Evaluation Washington, District Of Columbia Assignment Description The District of Columbia
More informationRethinking Recommendations for Use of Pneumococcal Vaccines in Adults
VACCINES Bruce Gellin and John F. Modlin, Section Editors INVITED ARTICLE Rethinking Recommendations for Use of Pneumococcal Vaccines in Adults Cynthia G. Whitney, 1 William Schaffner, 2 and Jay C. Butler
More informationRoutine Adult Immunization: American College of Preventive Medicine Practice Policy Statement, updated 2002
Routine Adult Immunization: American College of Preventive Medicine Practice Policy Statement, updated 2002 Ann R. Fingar, MD, MPH, and Byron J. Francis, MD, MPH Burden of suffering Vaccines are available
More informationIMPACT #: Local Inventory #: form 04. Age at admission: d. mo yr. Postal code:
- Date of birth: birth: Date of admission: year month day year month day Age at admission: d mo yr Postal code: Ethnic code: Hospital: Gender: 1 = male 2 = female 1 = Impact 2 = Other local, specify: Code
More information